FDA Approves Leucovorin for Cerebral Folate Deficiency in Children

The U.S. Food and Drug Administration (FDA) has approved leucovorin, a drug traditionally used to mitigate chemotherapy side effects, for the treatment of cerebral folate deficiency in children. This condition is associated with developmental delays and autism-like symptoms, including communication difficulties and repetitive behaviors.

FDA Commissioner Dr. Marty Makary announced that the agency would expedite the label change for leucovorin, enabling state Medicaid programs to cover the medication. He emphasized the administration's commitment to conducting further research on leucovorin as a therapy. President Donald Trump expressed optimism about the approval, stating, "This gives hope to the many parents with autistic children that it may be possible to improve their lives."

The decision has elicited mixed reactions from the autism community. The Autism Science Foundation noted that a higher standard of scientific evidence is necessary to determine leucovorin's efficacy and safety for autism treatment. While the organization does not currently recommend the drug based on existing evidence, it welcomes additional investigation into leucovorin.

Cerebral folate deficiency involves low levels of folate in the brain, a B vitamin essential for neural development. Research has identified that some children with autism symptoms have normal blood folate levels but reduced brain folate levels, potentially due to antibodies blocking folate transport into the brain. Studies have shown that approximately 75% of children with autism possess these antibodies.

Clinical trials have explored leucovorin's potential benefits for children with autism. A 2013 study found that one-third of treated children experienced moderate to significant improvements in communication skills compared to a control group. Subsequent studies in various countries have reported similar findings. However, experts caution that leucovorin is not a universal solution for autism and that treatment should be individualized.

The FDA's approval has raised concerns about the precedent it sets for drug approvals based on limited evidence. Some experts argue that the decision could provide false hope to families seeking effective treatments. Additionally, there is apprehension that the high-profile announcement may lead parents to self-administer over-the-counter folinic acid supplements, which differ from prescription leucovorin and may not provide the intended therapeutic effects.

The FDA has stated that it will release its scientific review of leucovorin and publish a manuscript in the near future. The agency also plans to issue updated prescribing information to ensure the safe and effective use of leucovorin for treating cerebral folate deficiency in both adults and pediatric patients.